“Barring fire, major eartherquakes, or volcanic catastrophe, concrete is good for centuries – the Pantheon has been in continuous use since 126AD. The long expected life and high initial cost of biomanufacturing buildings and equipment builds legacy into the system from the start. And the imperatives of launching a new biotechnology industry in the 1980s led to the building of many facilities within a few years to product the first wave of recombinant DNA products.”
(The Dinosaurs Can Evolve – Some Examples of Bioprocess Legacies in Action by Ellen M. Martin)
CHO expression is a legacy in several senses. In use since the 1980s, CHO systems today produce four of the top five blockbuster biologic products and remain the most common cell expression technology (making – 70% of biologics). How did CHO cells hold on to that dominance for a quarter of a century despite the hundreds of alternative expression systems that have emerged? Many alternative expression companies were founded with the expectation of beating the cost of CHO production, only to find the bar rising higher than when they were funded. The industry is partial to CHO, so we keep inventing new ways to get continual improvement out of CHO systems.
Download more information and other examples of bioprocess legacies for both upstream and downstream: The Dinosaurs Can Evolve by Ellen M. Martin
Included in Track 1 and 2 of BioProduction 2013 are talks that will address a mixture of CHO and alternative expression systems. Mark Ellis from UCB Celltech will talk about their experiences of using E. coli periplasmic expression of Fab’ fragments whilst Dr Gavin Davey from Trinity College Dublin, will talk about controlling N- and O- linked glycosylation in CHO cells.